• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Publication Library / Publications

Methodology of a novel risk stratification algorithm for patients with multiple myeloma in the relapsed setting

Introduction

Risk stratification tools provide valuable information to inform treatment decisions. Existing algorithms for patients with multiple myeloma (MM) were based on patients with newly diagnosed disease, and these have not been validated in the relapsed setting or in routine clinical practice. We developed a risk stratification algorithm (RSA) for patients with MM at initiation of second-line (2L) treatment, based on data from the Czech Registry of Monoclonal Gammopathies.

Methods

Predictors of overall survival (OS) at 2L treatment were identified using Cox proportional hazards models and backward selection. Risk scores were obtained by multiplying the hazard ratios for each predictor. The K-adaptive partitioning for survival (KAPS) algorithm defined four groups of stratification based on individual risk scores.

Results

Performance of the RSA was assessed using Nagelkerke’s R2 test and Harrell’s concordance index through Kaplan–Meier analysis of OS data. Prognostic groups were successfully defined based on real-world data. Use of a multiplicative score based on Cox modeling and KAPS to define cut-off values was effective.

Conclusion

Through innovative methods of risk assessment and collaboration between physicians and statisticians, the RSA was capable of stratifying patients at 2L treatment by survival expectations. This approach can be used to develop clinical decision-making tools in other disease areas to improve patient management.

Authors W Bouwmeester, A Briggs, B van Hout, R Hajek, S Gonzalez-McQuire, M Campioni, L DeCosta, L Brozova
Journal Oncology and Therapy
Therapeutic Area Oncology
Center of Excellence Real-world Evidence & Data Analytics
Year 2019
Read full article

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2025. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top